In summary, the present study for the first time demonstrates robust NIS expression and radioiodine uptake in several non-thyroid cancer cells by simultaneously targeting the MAP kinase and PI3K/Akt pathways and HDAC using their inhibitors. The gene discussed is AKT1; the disease is thyroid cancer.